RS62695B1 - Novi jak1 selektivni inhibitori i njihove upotrebe - Google Patents

Novi jak1 selektivni inhibitori i njihove upotrebe

Info

Publication number
RS62695B1
RS62695B1 RS20211521A RSP20211521A RS62695B1 RS 62695 B1 RS62695 B1 RS 62695B1 RS 20211521 A RS20211521 A RS 20211521A RS P20211521 A RSP20211521 A RS P20211521A RS 62695 B1 RS62695 B1 RS 62695B1
Authority
RS
Serbia
Prior art keywords
selective inhibitors
jak1 selective
novel
novel jak1
inhibitors
Prior art date
Application number
RS20211521A
Other languages
English (en)
Inventor
Congxin Liang
Original Assignee
Highlightll Pharmaceutical Hainan Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Highlightll Pharmaceutical Hainan Co Ltd filed Critical Highlightll Pharmaceutical Hainan Co Ltd
Publication of RS62695B1 publication Critical patent/RS62695B1/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14Ortho-condensed systems
    • C07D491/147Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Catalysts (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
RS20211521A 2016-10-03 2017-09-30 Novi jak1 selektivni inhibitori i njihove upotrebe RS62695B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662403660P 2016-10-03 2016-10-03
EP17858944.6A EP3509591B1 (en) 2016-10-03 2017-09-30 Novel jak1 selective inhibitors and uses thereof
PCT/US2017/054668 WO2018067422A1 (en) 2016-10-03 2017-09-30 Novel jak1 selective inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
RS62695B1 true RS62695B1 (sr) 2022-01-31

Family

ID=61831161

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20211521A RS62695B1 (sr) 2016-10-03 2017-09-30 Novi jak1 selektivni inhibitori i njihove upotrebe

Country Status (21)

Country Link
US (2) USRE49834E1 (sr)
EP (1) EP3509591B1 (sr)
JP (1) JP7089141B2 (sr)
KR (1) KR102399848B1 (sr)
CN (2) CN108366994B (sr)
AU (3) AU2017339417C1 (sr)
BR (1) BR112019005969A2 (sr)
CA (1) CA3039178A1 (sr)
DK (1) DK3509591T3 (sr)
EA (1) EA201990523A1 (sr)
ES (1) ES2901216T3 (sr)
HK (1) HK1253040A1 (sr)
HR (1) HRP20211965T1 (sr)
HU (1) HUE058120T2 (sr)
IL (3) IL265358B (sr)
MX (1) MX2019003649A (sr)
NZ (1) NZ751284A (sr)
PL (1) PL3509591T3 (sr)
PT (1) PT3509591T (sr)
RS (1) RS62695B1 (sr)
WO (1) WO2018067422A1 (sr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7839138B2 (en) * 2007-01-29 2010-11-23 Electro Scientific Industries, Inc. Adjustable force electrical contactor
PL3509591T3 (pl) 2016-10-03 2022-01-31 Highlightll Pharmaceutical (Hainan) Co., Ltd. Nowe selektywne inhibitory Jak1 i ich zastosowanie
EP3568396B1 (en) 2017-01-11 2020-11-11 Leo Pharma A/S Novel amino-imidazopyridine derivatives as janus kinase inhibitors and pharmaceutical use thereof
JP7431845B2 (ja) 2018-10-31 2024-02-15 インサイト・コーポレイション 血液疾患の治療のための併用療法
MA55201A (fr) * 2019-03-05 2022-01-12 Incyte Corp Inhibiteurs de la voie jak1 pour le traitement d'un dysfonctionnement chronique de l'allogreffe pulmonaire
JP2022526301A (ja) * 2019-03-19 2022-05-24 インサイト・コーポレイション 尋常性白斑のバイオマーカー
AU2020289149B2 (en) * 2019-06-06 2023-05-11 Hangzhou Highlightll Pharmaceutical Co., Ltd. Synthesis method of furoimidazopyridine compound, crystal form of furoimidazopyridine compound, and crystal form of salt thereof
EP4385511A3 (en) 2019-06-06 2024-08-07 Hangzhou Highlightll Pharmaceutical Co., Ltd. Method for synthesizing furoimidazopyridine compound, polymorphic substance and polymorphic substance of salt
EP4153566A1 (en) 2020-05-19 2023-03-29 Bayer CropScience Aktiengesellschaft Azabicyclic(thio)amides as fungicidal compounds
CN116057056A (zh) 2020-06-10 2023-05-02 拜耳公司 作为杀真菌剂的氮杂双环取代的杂环化合物
EP4351584A1 (en) * 2021-06-07 2024-04-17 The Regents of the University of California Compositions and methods for treating celiac disease
WO2023035913A1 (en) * 2021-09-13 2023-03-16 Hangzhou Highlightll Pharmaceutical Co., Ltd Methods of treating cns disorders
CN114213424B (zh) * 2021-12-30 2023-05-26 杭州高光制药有限公司 一种呋喃[3,2-b]并吡啶衍生物的合成方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4369172A (en) 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
EP0188040B1 (en) 1985-01-11 1991-08-14 Abbott Laboratories Limited Slow release solid preparation
JP2773959B2 (ja) 1990-07-10 1998-07-09 信越化学工業株式会社 大腸内放出性固形製剤
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
DE69924735T2 (de) 1998-07-28 2006-01-19 Tanabe Seiyaku Co., Ltd. Zur wirkstoffabgabe an zielorten im darm fähige zubereitung
JP2000119271A (ja) * 1998-08-12 2000-04-25 Hokuriku Seiyaku Co Ltd 1h―イミダゾピリジン誘導体
US6461631B1 (en) 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
US6800663B2 (en) 2002-10-18 2004-10-05 Alkermes Controlled Therapeutics Inc. Ii, Crosslinked hydrogel copolymers
EP1720855A4 (en) * 2004-03-02 2008-12-17 Smithkline Beecham Corp HEMMER OF ACT ACTIVITY
CN101282761A (zh) * 2005-08-04 2008-10-08 西特里斯药业公司 作为sirtuin调节剂的苯并咪唑衍生物
AU2010300719A1 (en) * 2009-09-29 2012-05-03 Xcovery Holding Company Llc PI3K (delta) selective inhibitors
WO2012022045A1 (en) * 2010-08-20 2012-02-23 Hutchison Medipharma Limited Pyrrolopyrimidine compounds and uses thereof
MX2013003913A (es) * 2010-10-08 2013-09-26 Abbvie Inc Compuestos de furo [3, 2-d] pirimidina.
WO2013007768A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
AU2012295802B2 (en) * 2011-08-12 2017-03-30 Nissan Chemical Industries, Ltd. Tricyclic heterocyclic compounds and JAK inhibitors
MX2015005428A (es) * 2012-11-01 2015-07-21 Incyte Corp Derivados triciclicos fusionados de tiofeno como inhibidores de la cinasa janus (jak).
EP3060234A1 (en) 2013-10-24 2016-08-31 AbbVie Inc. Jak1 selective inhibitor and uses thereof
WO2015168246A1 (en) 2014-04-30 2015-11-05 Incyte Corporation Processes of preparing a jak1 inhibitor and new forms thereto
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
PL3509591T3 (pl) 2016-10-03 2022-01-31 Highlightll Pharmaceutical (Hainan) Co., Ltd. Nowe selektywne inhibitory Jak1 i ich zastosowanie

Also Published As

Publication number Publication date
IL291265A (en) 2022-05-01
DK3509591T3 (da) 2021-12-20
IL291265B1 (en) 2023-01-01
AU2022201058A1 (en) 2022-03-10
IL291265B2 (en) 2023-05-01
IL291267B1 (en) 2023-01-01
USRE49834E1 (en) 2024-02-13
PL3509591T3 (pl) 2022-01-31
ES2901216T3 (es) 2022-03-21
CA3039178A1 (en) 2018-04-12
AU2022201061B2 (en) 2023-03-16
AU2017339417B2 (en) 2021-11-18
CN113214278B (zh) 2022-10-28
AU2017339417A1 (en) 2019-03-28
AU2022201061A1 (en) 2022-03-10
KR20190057069A (ko) 2019-05-27
CN108366994A (zh) 2018-08-03
IL265358A (en) 2019-05-30
IL265358B (en) 2022-04-01
US20190256523A1 (en) 2019-08-22
AU2017339417C1 (en) 2022-06-02
EA201990523A1 (ru) 2019-10-31
CN113214278A (zh) 2021-08-06
EP3509591A1 (en) 2019-07-17
PT3509591T (pt) 2021-12-27
EP3509591B1 (en) 2021-11-17
EP3509591A4 (en) 2020-03-25
HUE058120T2 (hu) 2022-07-28
HRP20211965T1 (hr) 2022-03-18
CN108366994B (zh) 2021-10-01
BR112019005969A2 (pt) 2019-06-18
JP2019537559A (ja) 2019-12-26
NZ751284A (en) 2022-09-30
JP7089141B2 (ja) 2022-06-22
US10738060B2 (en) 2020-08-11
IL291267B2 (en) 2023-05-01
HK1253040A1 (zh) 2019-06-06
AU2022201058B2 (en) 2023-03-16
KR102399848B1 (ko) 2022-05-19
IL291267A (en) 2022-05-01
MX2019003649A (es) 2019-08-14
WO2018067422A1 (en) 2018-04-12

Similar Documents

Publication Publication Date Title
IL265922A (en) tyk2 inhibitors and uses thereof
IL266109A (en) tyk2 inhibitors and uses thereof
IL291265A (en) Selective jak1 inhibitors and their uses
IL271999A (en) TYK2 inhibitors and uses thereof
HK1256997A1 (zh) Tyk2抑制劑及其用途
HK1248690A1 (zh) 酪胺酸蛋白質激酶2(tyk2)抑制劑及其用途
GB201605126D0 (en) Inhibitors and their uses
ZA201906875B (en) Jak1 selective inhibitors
IL263949A (en) Complement inhibitors and their uses
HK1249108A1 (zh) Mir-92抑制劑及其用途
HK1250926A1 (zh) 抑制劑及其應用
HK1255029A1 (zh) 明膠酶抑制劑及其用途
GB201505975D0 (en) Inhibitors and their uses
GB201505971D0 (en) Inhibitors and their uses
GB201404332D0 (en) Selective glycosidase inhibitors and uses thereof
GB201404330D0 (en) Selective glycosidase inhibitors and uses thereof
GB201404335D0 (en) Selective glycosidase inhibitors and uses thereof